Lincoln Park Capital, an institutional investor based in Chicago, has struck a deal to purchase as much as $25 million of shares in Triangle-based medical device firm TransEnterix.

“The Company expects this Commitment to provide us with additional balance sheet strength and to help continue funding our [surgical robot] Senhance regulatory and commercial efforts,” TransEnterix CEO Todd Pope said in a statement.

TransEnterix “will have the right, in its sole discretion, to sell to Lincoln Park up to $25.0 million in shares of the Company’s common stock over a 36-month period,” the company said.

TransEnterix shares trade on NYSE MKT under the symbol TRXC.